Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum View Full Press Release Travere Therapeutics Announces Planned Chief Executive Officer Transition Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)